#Inventory realistic fps prefab full#
We continue to prepare, and will be ready to launch the migraine indication soon after receiving full FDA approval. As previously disclosed during the third quarter of 2016, the FDA granted a tentative approval to our supplemental new drug application requesting a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults. In addition, total net product sales for the third quarter of 2016 were $55.6 million, representing solid growth of 44% over the same period last year. Trokendi XR prescriptions for third quarter 2016 totaled 9,949 prescriptions, which is a 32% increase over the same quarter last year and Oxtellar XR prescriptions for the third quarter of 2016 totaled 32,259 prescriptions representing an increase of 26% over the same quarter last year. Total prescriptions for Trokendi XR and Oxtellar XR combined in the third quarter, as reported by IMS, were 131,308 representing an increase of 30% over the third quarter of 2015. We’re pleased with the progress we’ve made towards meeting our 2016 goals, reaching year-to-date net product sales of $149 million, a 48% increase over the same period last year. Strong growth in product prescriptions and net product sales continue to reflect the solid underlying demand for our commercial products. Thank you, Peter, good morning everyone, and thanks for taking the time to join us as we discuss our 2016 third quarter business update.
#Inventory realistic fps prefab update#
Supernus declines any obligation to update these forward-looking statements except as required by applicable securities laws. Please reference the company’s most recent press release and current filings with the SEC including the company’s 8-K that was filed this morning. Since then, the company may have made additional announcements related to the topics discussed.
For the benefit of those who may be listening to the replay of this call is being held and recorded on November 14, 2016, at approximately 9:00 a.m. Actual results may differ materially from those projected in these forward-looking statements. These forward-looking statements reflect Supernus’ current perspective on existing trends and information and can be identified by such words as expect, plan, will, may, anticipate, believe, should, intend and other words of similar meaning.Īny such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. We expect the duration of the call to be approximately 45 minutes.ĭuring the course of this call, management may make certain forward-looking statements regarding future events in the company’s future performance. Following remarks by management, we will open the call to questions.
Today’s call is being made available via the Investor Relations section of the company’s website at ir. On the call with me today are Supernus’ Chief Executive Officer, Jack Khattar, and Chief Financial Officer Greg Patrick. The company issued a press release this morning announcing this update. The update discussed today is for the three months ended September 30, 2016. Good morning everyone, and thank you for joining us today for Supernus Pharmaceuticals’ third quarter 2016 business update conference call. I would now like to turn the conference over to Peter Vozzo of Westwicke Partners, Investor Relations for Supernus Pharmaceuticals. As a reminder, this conference call is being recorded. Later we will conduct a question-and-answer session and instructions will follow at that time. At this time, all participants are in a listen-only mode.
Good morning ladies and gentlemen, and welcome to the Supernus Pharmaceuticals’ Third Quarter 2016 Business Update Conference Call. (NASDAQ: SUPN) Q3 2016 Earnings Conference Call Novem9:00 AM ET
0 kommentar(er)
